Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.

Ulmert, David LU ; Evans, Michael J ; Holland, Jason P ; Rice, Samuel L ; Wongvipat, John ; Pettersson, Kim ; Abrahamsson, Per-Anders LU ; Scardino, Peter T ; Larson, Steven M and Lilja, Hans LU orcid , et al. (2012) In Cancer Discovery 2(4). p.320-327
Abstract
Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clinical biomarker could more clearly assess the advantages of imaging cancer. The virtues and shortcomings of measuring secreted prostate-specific antigen (PSA), an androgen receptor (AR) target gene, in patients with prostate cancer are well documented, making it a logical candidate for assessing whether a radiotracer can reveal new (and useful) information beyond that conferred by serum PSA. Therefore, we developed (89)Zr-labeled 5A10, a novel radiotracer that targets "free" PSA. (89)Zr-5A10 localizes in... (More)
Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clinical biomarker could more clearly assess the advantages of imaging cancer. The virtues and shortcomings of measuring secreted prostate-specific antigen (PSA), an androgen receptor (AR) target gene, in patients with prostate cancer are well documented, making it a logical candidate for assessing whether a radiotracer can reveal new (and useful) information beyond that conferred by serum PSA. Therefore, we developed (89)Zr-labeled 5A10, a novel radiotracer that targets "free" PSA. (89)Zr-5A10 localizes in an AR-dependent manner in vivo to models of castration-resistant prostate cancer, a disease state in which serum PSA may not reflect clinical outcomes. Finally, we demonstrate that (89)Zr-5A10 can detect osseous prostate cancer lesions, a context where bone scans fail to discriminate malignant and nonmalignant signals. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Discovery
volume
2
issue
4
pages
320 - 327
publisher
American Association for Cancer Research
external identifiers
  • wos:000306327000026
  • pmid:22576209
  • scopus:84866146188
ISSN
2159-8274
DOI
10.1158/2159-8290.CD-11-0316
language
English
LU publication?
yes
id
9ccc0ce4-5a56-4d6a-b51d-15109b815792 (old id 2608922)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22576209?dopt=Abstract
date added to LUP
2016-04-04 08:55:43
date last changed
2022-05-16 22:23:16
@article{9ccc0ce4-5a56-4d6a-b51d-15109b815792,
  abstract     = {{Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clinical biomarker could more clearly assess the advantages of imaging cancer. The virtues and shortcomings of measuring secreted prostate-specific antigen (PSA), an androgen receptor (AR) target gene, in patients with prostate cancer are well documented, making it a logical candidate for assessing whether a radiotracer can reveal new (and useful) information beyond that conferred by serum PSA. Therefore, we developed (89)Zr-labeled 5A10, a novel radiotracer that targets "free" PSA. (89)Zr-5A10 localizes in an AR-dependent manner in vivo to models of castration-resistant prostate cancer, a disease state in which serum PSA may not reflect clinical outcomes. Finally, we demonstrate that (89)Zr-5A10 can detect osseous prostate cancer lesions, a context where bone scans fail to discriminate malignant and nonmalignant signals.}},
  author       = {{Ulmert, David and Evans, Michael J and Holland, Jason P and Rice, Samuel L and Wongvipat, John and Pettersson, Kim and Abrahamsson, Per-Anders and Scardino, Peter T and Larson, Steven M and Lilja, Hans and Lewis, Jason S and Sawyers, Charles L}},
  issn         = {{2159-8274}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{320--327}},
  publisher    = {{American Association for Cancer Research}},
  series       = {{Cancer Discovery}},
  title        = {{Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.}},
  url          = {{http://dx.doi.org/10.1158/2159-8290.CD-11-0316}},
  doi          = {{10.1158/2159-8290.CD-11-0316}},
  volume       = {{2}},
  year         = {{2012}},
}